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Abstract
Interferon alpha (IFNα) may play a significant role in systemic lupus erythematosus (SLE)
pathogenesis. Recent literature suggests that IFNα does not correlate with disease activities and
blockade of IFNα is not effective in treating SLE. This study aims to delineate further the role of
IFNα in SLE. 12-week old NZM2328 and its congenic NZM2328.Lc1R27 (R27) female mice
were challenged with adenovirus-IFNα (adeno-IFNα) or adenovirus-LacZ (adeno-LacZ). Only
adeno-IFNα treated NZM2328 developed severe proteinuria and died of chronic
glomerulonephritis (GN) and end stage renal disease. Adeno-IFNα treated R27 did develop
immune complex-mediated GN but had normal renal function. Adeno-LacZ treated NZM2328
showed enlarged glomeruli and increased cellularity without immune complex deposition. Adeno-
LacZ treated R27 did not show serological and histological abnormalities. Adeno-IFNα induced
anti-dsDNA and anti-kidney autoantibodies in NZM2328 and R27. These results suggest that end
organ damage is host-dependent and less related to autoimmunity and may have significant
implications in SLE pathogenesis.
© 2014 Published by Elsevier Inc.
*Corresponding author at: Box 800133, University of Virginia Health System, Charlottesville, VA 22908-0133, USA. Fax: +1 434 924
9578.
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1. Introduction
Systemic lupus erythematosus (SLE) is an autoimmune disease affecting multiple organs
with complex pathogenesis [1]. The clinical presentation of SLE at the initial diagnosis and
at relapse is variable. Among the implicated cytokines, interferon α (IFNα) was first
reported to be elevated in the plasma of patients with SLE and other autoimmune diseases in
1979 [2]. With the advent of the concept that an “interferon signature” is present in patients'
peripheral blood [3,4], considerable interest in this cytokine has been rekindled (reviewed in
[5,6]). The findings that ANA and anti-dsDNA antibodies are induced in patients treated
with IFNα and that SLE develops in a small proportion of these ANA positive patients
further reinforce the notion that IFNα may play a crucial pathogenic role (reviewed in [7]).
Despite this initial enthusiasm, longitudinal studies of lupus patients did not show a
correlation of IFNα levels with disease activity [8,9]. In addition, blocking IFNα as a
therapeutic strategy has resulted in disappointing results (reviewed in [6]). Thus, the exact
role of IFNα in SLE remains to be delineated further.
Our laboratory has used NZM2328 as a model for lupus nephritis (LN) [10–12]. LN and end
stage renal disease (ESRD) develops preferentially in female mice in this model [10].
Genetic studies showed that autoantibody production and susceptibility to development of
ESRD were under separate genetic control [10,11]. The phenotype of NZM2328.Lc4 is the
development of LN and ESRD in female mice without ANA and anti-dsDNA antibodies,
providing evidence that these antibodies are not required for the development of fatal LN
[11]. Recently our laboratory generated a congenic strain NZM2328.Lc1R27 (R27) whose
disease phenotype showed that chronic glomerulonephritis (GN) and immune complex-
mediated acute GN are under separate genetic control and that immune complex-mediated
GN need not progress to chronic GN leading to ESRD [12]. Studies of GN pathogenesis in
NZM2328 and its congenic strain R27 now allow us to delineate the role of IFNα in LN. We
show here that young NZM2328 treated with IFNα developed accelerated GN and exhibited
all the features of spontaneous LN found in older NZM2328 mice, including severe
proteinuria, chronic glomerular nephritis, as well as early mortality. In contrast R27 injected
with adeno-IFNα are resistant to chronic kidney damage, even though autoantibody-
mediated autoimmunity is induced.
2. Materials and methods
2.1. Mice and IFNα
NZM2328 mice were originally purchased from the Jackson Laboratory [10], and R27 were
generated by our laboratory [12]. Only female mice were used. Adenovirus containing
interferon alpha (adeno-IFNα) and control virus adeno-LacZ were used as described [13].
Adeno-IFNα and adeno-LacZ lysates were amplified in early passage in 293T cells, and the
titer was determined by using Adeno Rapid Titer Kit (Clontech).
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2.2. Study design
12 week old female NZM2328 or R27 mice were injected with 5 × 107 particles of adeno-
IFNα or adeno-LacZ. The mice were followed for 2 months by monitoring weekly for the
development of severe proteinuria (>300 mg/dl) with Multistix 10 SG (SIEMENS) and anti-
dsDNA antibodies by ELISA [10]. Moribund mice were euthanized and perfused with PBS
before collecting kidneys for further studies. Mice in the control groups injected with the
vector adeno-LacZ were sacrificed at sixty days after the injection of the virus. Adeno-IFNα
treated R27 were sacrificed either 8 weeks after viral injection or followed for nine months
after the treatment.
2.3. Methods
Sera and urine were collected weekly or before euthanization. Serum BUN and urinary
albumin/creatinine ratios were determined as described [12]. IgG, C3 and IgG2 deposition in
kidneys by direct immunofluorescence, splenocyte cell surface marker expression by flow
cytometry, serum anti-dsDNA antibodies by ELISA and ANA on 3T3 cells by
immunofluores-cence were carried out as described [12]. Renal Ig eluates were used in
Western blot analysis with kidney lysate from two month old NZM2328 as the substrate as
described [12]. Two-tailed unpaired Student t-tests were used to evaluate the significance of
the results with assigned p-values.
3. Results
3.1. Acceleration of fatal GN in NZM2328 with adeno-IFNα
In a preliminary experiment, it was determined that 5 × 107 adeno-IFNα viral particles given
intravenously induced the development of fatal GN within 6 weeks after they were injected
into 12 week old NZM2328 female mice. This dose of adeno-IFNα was used in subsequent
experiments. 5 × 107 adeno-LacZ viral particles were used as control virus and injected into
a cohort of NZM2328 as the control group. As shown in Fig. 1A, 12 week old NZM2328
mice (n = 7) injected with adeno-IFNα developed severe proteinuria at different time points
after the injection. By 5 weeks after the injection, all the treated mice developed severe
proteinuria. Shortly after the development of severe proteinuria, the affected mice were
sacrificed because they appeared to be moribund. The mortality curve mirrored the
proteinuria curve (Fig. 1B). Adeno-LacZ (n = 9) treated NZM2328 mice did not develop
severe proteinuria or die prematurely (Figs. 1A and B). The urinary albumin/creatinine
ratios and blood urea nitrogen levels in adeno-IFNα treated NZM2328 mice (n = 8) and
adeno-LacZ treated control group (n = 4) were examined 4 weeks after viral injection.
Adeno-IFNα treated NZM2328 group showed significantly more proteinuria and higher
BUN than the control adeno-LacZ treated NZM2328 group (Figs. 1C and D). Importantly,
all 8 adeno-IFNα treated mice had elevated BUN, indicative of renal failure. H&E staining
of the kidneys obtained at the end of the experiments showed that adeno-IFNα treated
NZM2328 mice had chronic GN with sclerotic glomeruli, obliteration of the Bowman's
capsule space, tubular dilatation, and mild interstitial infiltrate (Fig. 2A). In contrast,
enlarged glomeruli without tubular or interstitial infiltrate were observed in adeno-LacZ
treated NZM2328 mice (Fig. 2A).
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3.2. Resistance of R27 mice to the development of adeno-IFNα accelerated fatal GN and
end stage renal failure
R27 mice developed immune complex-mediated acute GN without progression to chronic
GN and ESRD due to kidney resistance to damage [11]. In view of the ability of adeno-
IFNα to accelerate the development of LN in the parental strain NZM2328, adeno-IFNα and
adeno-LacZ were injected into two cohorts of R27 mice. R27 mice injected with adeno-
IFNα were free of symptoms. None of the mice in this group had severe proteinuria or died
during the 8 weeks following up (Figs. 1A and B). 8 weeks after injection, the urine and
blood were collected and tested, the urinary albumin/creatinine ratios and blood urea
nitrogen levels were normal (Figs. 1C and D). H&E staining showed enlarged glomeruli
with moderate cellular infiltrate without sclerosis or tubular or interstitial abnormalities (Fig.
2A). Three of this cohort were followed for 9 months. None of them showed severe
proteinuria or died. As a control, a cohort of R27 was treated with adeno-LacZ. These
control mice did not have proteinuria, early mortality, micro-proteinuria or increased BUN
and their kidneys showed normal histology.
3.3. Enhanced immune complex deposition and autoantibody production in NZM2328 and
R27 treated with adeno-IFNα
As shown in Fig. 2B, IgG, IgG2a and C3 were deposited in the glomeruli in the kidneys of
NZM2328 and R27 injected with adeno-IFNα. The staining intensities were similar between
these two groups. H&E stain showed evidence of mildly enlarged glomeruli and increased
cellularity in the glomeruli of NZM2328 treated with adeno-LacZ. Little IgG and C3
deposits were seen in these glomeruli.
Circulating anti-dsDNA antibodies were measured in both adeno-IFNα treated NZM2328
and R27 mice. As shown in Fig. 3A, anti-dsDNA antibodies were readily detected in the
sera of five out of five NZM2328 mice and one out of four R27 mice obtained 14 days after
injection of the virus. The titers of these antibodies were similar in sera obtained on day 28
after the injection, although only four out of five NZM2328 were high. It is of interest to
note that in the terminal sera of IFNα-treated NZM2328 (6 weeks or less after injection of
the virus), only one out of four had significant anti-dsDNA antibodies in comparison to four
out of four IFNα-treated R27 mice (eight weeks after the injection of virus). Significant anti-
dsDNA was not found in the adeno-LacZ treated mice from both strains at all times. Three
of the IFNα treated R27 mice were followed up to nine months after the injection of the
virus. They had circulating anti-dsDNA antibodies (Fig. 3A). Only 5% (1/21) of the IFNα
treated NZM2328 had positive ANA at 1:50 dilution. All the mice in the other groups were
negative for ANA. In Western blot analysis (Fig. 3B), both IFNα-treated NZM2328 and
R27 mice had antibodies against kidney cell lysates. It appears that more cell reactive
antibodies were detected in IFNα treated R27 mice. Although not shown, eluates obtained
from kidneys at 8 weeks after injection or from terminally-ill mice had anti-dsDNA
antibodies by ELISA and anti-kidney cell lysate antibodies by Western blot analysis. Both
NZM2328 and R27 treated with adeno-IFNα showed predominantly Th1 mediated anti-
dsDNA antibody response (Fig. 3C). As expected, IgG2a anti-dsDNA antibodies accounted
for about 70% of the total IgG anti-dsDNA antibodies in both groups. Spleen size and flow
cytometry analysis of lymphocyte subsets, macrophages and dendritic cells showed no
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differences between IFNα treated R27 and NZM2328 mice. In addition, the cell subsets
were not different from those in aged NZM2328 with spontaneous LN.
4. Discussion
4.1. Adeno-IFNα accelerated fatal GN in NZM2328 as a novel model for LN
In this study, it is documented that adeno-IFNα accelerated the development of immune
complex-mediated lupus GN in NZM2328. Under the experimental conditions, the treated
mice developed fatal GN 3–6 weeks after the injection of the viral particles. The kinetics of
GN development was very similar to that reported by Jacob et al. [14]. The lymphocyte
subsets, macrophages and dendritic cells in these treated mice were not different from those
of NZM2328 with spontaneous disease as they age. In addition, preliminary data have been
obtained showing that intra-glomerular macrophage populations were similar between the
IFNα treated NZM2328 and those with spontaneous LN. The various intra-renal lymphocyte
and macrophage populations did not differ from each other. Renal cytokine expression was
similar between these two groups (S-S J Sung and C Dai, unpublished). These results
support the thesis that adeno-IFNα accelerated GN in NZM2328 is a suitable model for LN.
The advantage of this model is the uniformity of fatal GN development in a short period of
time. The utilization of this model would be both time- and resource-saving and may
facilitate screening of novel therapeutic agents. In fact this model has been used by us
recently to show that IL-1 could be a target for LN treatment [15].
4.2. Autoimmunity vs end organ damage
In this study, we document that IFNα has significant effects on the immune system of both
NZM2328 and R27. IFNα hastens the development of anti-dsDNA autoantibodies and anti-
kidney antibodies in both strains. Significant amounts of immune complexes and
complement are deposited in the kidneys of the adeno-IFNα treated NZM2328 and R27
mice. The observation that chronic GN and ESRD were seen in young IFNα treated
NZM2328 but not in similarly treated R27 adds support to our conclusion that anti-dsDNA
antibodies are not sufficient for the development of fatal LN and that immune complex-
mediated acute GN need not progress to chronic GN and ESRD [12].
It is of interest to note the mild enlargement of the glomeruli and increased cellularity in
adeno-LacZ treated NZM2328 without immune complex deposition. This observation
implies that viral infection by itself may induce acute GN. In addition, the lack of these
abnormalities in similarly treated R27 adds support to the conclusion that R27 kidney is also
resistant to virus-induced acute GN. Therefore end organ response to inflammation induced
by immune complex or viral infection is crucial in the determination of end organ damage.
The results from this study provide added evidence for the hypothesis that autoimmunity
(autoantibodies and autoreactive T cells) should be considered independently from end
organ damage (clinical manifestations).
4.3. Implications
The results from this study provide an explanation to the observation that IFNα levels do not
correlate with disease activity [8,9]. Although our studies have focused on LN, the
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conclusions could be extended to other clinical scenarios in SLE. Undoubtedly, genes that
are related to clinical manifestations remain to be discovered. For example, there may be
genes that control photosensitivity in SLE patients with anti-Ro60 autoantibodies. The
genetic differences among SLE patients provide an explanation to the question why some
patients have photosensitivity related skin rash while others may not have such clinical
manifestations although they may have similar autoantibodies. Our observations also explain
why only a small portion of patients with IFNα induced ANA and related autoantibodies
developed SLE.
The second issue is the apparent lack of efficacy in blocking IFNα in treating SLE
[reviewed in 6]. It is well documented that IFNα has profound effects on both the innate and
the adaptive immune response. These effects may not directly contribute to end organ
damage. IFNα may activate the cytokine network, which is more relevant to end organ
damage. If this cytokine network is activated and maintains its activation without further
input from IFNα, it is expected that blocking the IFNα pathway would not be effective. This
explanation may also be applied to the observation that rontalizumab, an IgG1 monoclonal
anti-IFNα antibody, reduced the number of lupus flares and steroid requirement in IFNα
signature negative lupus patients [6].
5. Conclusions
The present study suggests that IFNα is a potent inducer of autoimmune responses. Its effect
on end organ damage is host-dependent. This observation has significant implications for the
pathogenesis and treatment of SLE.
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Abbreviations
Adeno-IFNα adenovirus-IFNα
Adeno-LacZ adenovirus-LacZ
ANA anti-nuclear antibody
BUN blood urea nitrogen
ELISA enzyme-linked immunosorbent assay
ESRD end stage renal disease
GN glomerulonephritis
H&E hematoxylin and eosin
IFNα interferon α
IL-1 interleukin 1
LN lupus nephritis
R27 NZM2328.Lc1R27
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SLE systemic lupus erythematosus
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Figure 1.
Renal functions and survival kinetics of mice treated with adeno-IFNα and adeno-LacZ.
Adeno-IFNα induced severe proteinuria, early mortality, severe microalbuminuria and renal
failure in NZM2328 but not in R27 mice. 12 week old NZM2328 (n = 7) and R27 (n = 9)
were injected with 5 × 107 adeno-IFNα. As controls, 12 week old NZM2327 (n = 8) and
R27 (n = 4) were injected with adeno-LacZ. Only NZM2328-IFNα had proteinuria and early
mortality (panels A and B). Urinary albumin/creatinine ratios (panel C) and elevated BUN
(panel D) were measured 4 weeks after the injection of adeno-IFNα or adeno-LacZ virus
into NZM2328 and R27 mice. A representative experiment is presented. Similar results were
found in another experiment.
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Figure 2.
H&E histology and immunofluorescence of kidneys from representative mice. Panel A.
H&E staining of kidneys from an adeno-IFNα treated NZM2328 and an age matched adeno-
IFNα treated R27 mouse. Kidneys from mice treated with the control vector adeno-LacZ are
also shown. Panel B. IgG, C3 and IgG2 staining of kidney sections from same samples as in
A.
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Figure 3.
Adeno-IFNα induced anti-dsDNA and anti-kidney antibodies in NZM2328 and R27. Panel
A. anti-dsDNA ELISA of sera collected from mice 2, 4, 8 weeks after adeno-IFNα or
adeno-LacZ treatments or at the time of their being sacrificed for the virus treated NZM2328
mice due to severe proteinuria. Three mice of adeno-IFNα R27 were also analyzed at 9
months. Sera were diluted at 1:100. Panel B. anti-kidney antibodies detected by Western
blot analysis. Mouse kidney homogenate was used as the substrate and the sera were diluted
at 1:250. Lanes 1 to 4: sera from sick adeno-IFNα treatment NZM2328. Lanes 5 to 8, sera
from age matched adeno-IFNα treated R27. Lane 9 is negative control. Panel C. Anti-
dsDNA antibodies were tested with anti-IgG and anti-IgG isotype antibodies using sera from
three adeno-IFNα-treated NZM2328 mice (4 weeks) and three adeno-IFNα-treated R27
mice (8 weeks). Sera were diluted 1:100. This figure shows that anti-dsDNA antibodies
were predominantly of the IgG2a isotype.
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